Biotech Stock Still 700%: What Investors Should Do Today
A biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
A biotech stock still 700% has defied gravity, even as it slumps 30% this year. Learn how to read the signals, what a...
As the Federal Reserve prepares to announce policy, market nerves rise and major indexes stumble. This guide breaks d...
Oracle slipped this year, but does that mean it's a no-brainer AI buy? This practical guide weighs AI potential, fina...
Carvana’s stock run looked extraordinary, up 4,300% in three years. But the strongest buy signal wasn’t the hype—it w...
The Trade Desk slid again amid reports of agency cautions and analyst downgrades. This piece explains the drivers, wh...
Bitcoin climbs on rising demand from whales and regulated ETFs, suggesting more upside may be ahead. Here are the key...
A Friday executive order on mortgages is reshaping regulatory expectations, prioritizing smaller lenders while drawin...
Cleo Capital urges investors to recalibrate Nvidia's growth outlook as AI infrastructure spending moves from explosiv...
Cloudflare shares climbed about 8% on the day as investors bet NVIDIA’s AI acceleration will push more traffic throug...
Micron Technology is set to release quarterly results after the bell, with investors hoping for a blowout fueled by A...
A rare misfire during a live-fire demonstration over Camp Pendleton unleashed shrapnel on California's I-5. The Marin...
In a rapid 48-hour sprint, Congress advanced major child safety bills on both sides of the Capitol, signaling a new e...